Skip to main content
. 2019 Jul 4;16(4):683–697. doi: 10.1080/15548627.2019.1635380

Figure 1.

Figure 1.

MIR145-3p downregulation is associated with disease prognosis in human MM. (A) MIR145-3p expression in five MM cell lines (U266, NCI-H929, RPMI-8226, LP-1 and KM3) and normal plasma cells (PCs). MIR145-3p expression levels were calculated by the MIR145-3p:RNU6 expression ratio (i.e., 2−ΔCt). (B) Comparison of MIR145-3p expression in SDC1/CD138+ plasma cells from 30 newly diagnosis MM patients and 18 normal healthy donors via qRT-PCR. (C-F) Expression patterns of MIR145-3p with albumin (C), B2M (beta-2-microglobulin) (B), creatinine (E), and calcium (F) (all *P < 0.05; **P < 0.01). (G) Survival analysis of MM patients with low MIR145-3p expression using Kaplan-Meier curves. Low expression level of MIR145-3p was associated with shorter progression-free survival (PFS) (P < 0.05). The mean value was used as the cut-off point for definition of low and high MIR145-3p expression groups.